Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hope to patients. More than half of all clinical trials fail due to safety issues, resulting in a staggering $400 billion annual loss and delaying life-saving treatments for patients. Their proprietary platform, SAFEPATH, uses cutting-edge deep learning to address these challenges by uncovering the mechanisms behind drug toxicity. Unlike traditional safety assessments that identify what went wrong, SAFEPATH combines cheminformatics, bioinformatics, and multimodal data analysis to explain why and how safety issues occur, delivering actionable insights to refine or repurpose drug candidates. Ignota Labs is building a robust pipeline to bring safer drugs to market faster, partnering to develop and co-develop assets that might otherwise fail, and accelerating the delivery of vital therapies to patients in need. 

Dr. Layla Hosseini-Gerami will be giving a sponsor talk at the conference.

We are a Stockholm-based, independent biostatistics consultancy company, with a particular focus on survival analysis, tailored development of software packages, and training courses in biostatistics. All of our team members are PhD-trained biostatisticians, with extensive applied experience complemented by advanced methodological training. We have earned a strong reputation among national and international researchers, including renowned clinical professors at leading international universities and research institutes. 

As proud sponsors of this meeting, we’re excited to announce our upcoming Red Door Analytics Winter School in Biostatistics, taking place this November in Stockholm. This year’s program covers causal survival analysis and multi-state models. Please check our website to learn more about our work and get details about the Winter School: https://reddooranalytics.se